v3.26.1
Consolidated Statements of Changes in Equity - USD ($)
$ in Thousands
Share Capital
Additional paid-in capital
Retained earnings
Accumulated Other comprehensive income (loss)
Treasury shares (cost)
Non- controlling interests
Total
Balance at Dec. 31, 2022 $ 4,347 $ 145,369 $ 419,448 $ (17,030) $ (259) $ 625,047 $ 1,176,922
Balance (in Shares) at Dec. 31, 2022 15,317,667            
Net income (Loss) 64,014 101,718 165,732
Foreign currency translation (11,012) (12,274) (23,286)
Foreign currency translation from discontinued operations 7,590 11,379 18,969
Actuarial gain from defined benefit plans 1,362 631 1,993
Share of other comprehensive loss of companies accounted for at equity (575) (575)
Gain from investments in equity instruments measured at fair value through other comprehensive income (Note 8) 9,996 9,996
Total other comprehensive income (loss) 1,362 5,999 (264) 7,097
Total comprehensive income 65,376 5,999 101,454 172,829
Issuance of restricted shares to employees $ 4 (4)
Issuance of restricted shares to employees (in Shares) 15,000            
Cost of share-based payment (Note 20) 7,269 11,415 18,684
Dividend to Formula’s shareholders (9,605) (9,605)
Dividend to non-controlling interests in subsidiaries (62,487) (62,487)
Transactions with non-controlling interests due to holding changes, including exercise of employees’ stock options 5,803 643 6,446
Acquisition of non-controlling interests (923) (4,404) (5,327)
Settlement and expiration of put options over non-controlling interests (32) (1,029) (1,061)
Non-controlling interests arising from initially consolidated companies 11,784 11,784
Balance at Dec. 31, 2023 $ 4,351 157,482 475,219 (11,031) (259) 682,423 1,308,185
Balance (in Shares) at Dec. 31, 2023 15,332,667            
Net income (Loss) 79,670 114,120 193,790
Foreign currency translation (2,496) (3,461) (5,957)
Foreign currency translation from discontinued operations (2,849) (3,361) (6,210)
Actuarial gain from defined benefit plans 437 432 869
Share of other comprehensive loss of companies accounted for at equity (3,316) (3,316)
Gain from investments in equity instruments measured at fair value through other comprehensive income (Note 8) 6,272 6,272
Total other comprehensive income (loss) 437 (2,389) (6,390) (8,342)
Total comprehensive income 80,107 (2,389) 107,730 185,448
Cost of share-based payment (Note 20) 7,078 9,086 16,164
Dividend to Formula’s shareholders (19,312)   (19,312)
Dividend to non-controlling interests in subsidiaries (81,858) (81,858)
Transactions with non-controlling interests due to holding changes, including exercise of employees’ stock options (3,242) (8,812) (12,054)
Settlement and expiration of put options over non-controlling interests (8,666) (11,116) (19,782)
Non-controlling interests arising from initially consolidated companies 12,554 12,554
Balance at Dec. 31, 2024 $ 4,351 152,652 536,014 (13,420) (259) 710,007 $ 1,389,345
Balance (in Shares) at Dec. 31, 2024 15,332,667           15,332,667
Net income (Loss) 606,479 62,585 $ 669,064
Foreign currency translation 77,237 55,183 132,420
Foreign currency translation from discontinued operations (23,189) (4,173) (27,362)
Actuarial gain from defined benefit plans 719 731 1,450
Share of other comprehensive loss of companies accounted for at equity 101 101
Gain from investments in equity instruments measured at fair value through other comprehensive income (Note 8) (473) (473)
Total other comprehensive income (loss) 719 53,676 51,741 106,136
Total comprehensive income 607,198 53,676 114,326 775,200
Cost of share-based payment (Note 20) 7,286 23,861 31,147
Dividend to Formula’s shareholders (36,539) (36,539)
Dividend equivalents on RSUs to Formula’s shareholders (1,087) (1,087)
Dividend to non-controlling interests in subsidiaries (89,222) (89,222)
Transactions with non-controlling interests due to holding changes, including exercise of employees’ stock options 41,831 41,975 83,806
Acquisition of non-controlling interests (8,858) (8,858)
Settlement and expiration of put options over non-controlling interests (35,528) (10,019) (45,547)
Loss of control and deconsolidation of a subsidiary 37,088 (361,247) (324,159)
Other adjustments 183 183
Non-controlling interests arising from initially consolidated companies 3,533 3,533
Balance at Dec. 31, 2025 $ 4,351 $ 166,241 $ 1,105,586 $ 77,344 $ (259) $ 424,539 $ 1,777,802
Balance (in Shares) at Dec. 31, 2025 15,332,667           15,332,667